These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 34087391)

  • 1. Nano-ivabradine averts behavioral anomalies in Huntington's disease rat model via modulating Rhes/m-tor pathway.
    Saad MA; Ahmed MAE; Elbadawy NN; Abdelkader NF
    Prog Neuropsychopharmacol Biol Psychiatry; 2021 Dec; 111():110368. PubMed ID: 34087391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erythropoietin and Bacillus Calmette-Guérin Vaccination Mitigate 3-Nitropropionic Acid-Induced Huntington-like Disease in Rats by Modulating the PI3K/Akt/mTOR/P70S6K Pathway and Enhancing the Autophagy.
    Senousy MA; Hanafy ME; Shehata N; Rizk SM
    ACS Chem Neurosci; 2022 Mar; 13(6):721-732. PubMed ID: 35226456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel therapeutic application of solid lipid nanoparticles encapsulated thymoquinone (TQ-SLNs) on 3-nitroproponic acid induced Huntington's disease-like symptoms in wistar rats.
    Ramachandran S; Thangarajan S
    Chem Biol Interact; 2016 Aug; 256():25-36. PubMed ID: 27206696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ginsenoside Rg1 exerts neuroprotective effects in 3-nitropronpionic acid-induced mouse model of Huntington's disease via suppressing MAPKs and NF-κB pathways in the striatum.
    Yang X; Chu SF; Wang ZZ; Li FF; Yuan YH; Chen NH
    Acta Pharmacol Sin; 2021 Sep; 42(9):1409-1421. PubMed ID: 33214696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vildagliptin Attenuates Huntington's Disease through Activation of GLP-1 Receptor/PI3K/Akt/BDNF Pathway in 3-Nitropropionic Acid Rat Model.
    Sayed NH; Fathy N; Kortam MA; Rabie MA; Mohamed AF; Kamel AS
    Neurotherapeutics; 2020 Jan; 17(1):252-268. PubMed ID: 31728850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rhes deletion is neuroprotective in the 3-nitropropionic acid model of Huntington's disease.
    Mealer RG; Subramaniam S; Snyder SH
    J Neurosci; 2013 Feb; 33(9):4206-10. PubMed ID: 23447628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levothyroxine attenuates behavioral impairment and improves oxidative stress and histological alteration 3-nitropropionic acid induced experimental Huntington's disease in rats.
    Badini F; Bayrami A; Mirshekar MA; Shahraki S; Fanaei H
    Behav Brain Res; 2024 Mar; 461():114864. PubMed ID: 38220060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroprotective activity of tetramethylpyrazine against 3-nitropropionic acid induced Huntington's disease-like symptoms in rats.
    Danduga RCSR; Dondapati SR; Kola PK; Grace L; Tadigiri RVB; Kanakaraju VK
    Biomed Pharmacother; 2018 Sep; 105():1254-1268. PubMed ID: 30021362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lercanidipine boosts the efficacy of mesenchymal stem cell therapy in 3-NP-induced Huntington's disease model rats via modulation of the calcium/calcineurin/NFATc4 and Wnt/β-catenin signalling pathways.
    Elbaz EM; Helmy HS; El-Sahar AE; Saad MA; Sayed RH
    Neurochem Int; 2019 Dec; 131():104548. PubMed ID: 31539560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural and functional neuroprotection in a rat model of Huntington's disease by viral gene transfer of GDNF.
    McBride JL; During MJ; Wuu J; Chen EY; Leurgans SE; Kordower JH
    Exp Neurol; 2003 Jun; 181(2):213-23. PubMed ID: 12781994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of safranal or candesartan on 3-nitropropionicacid-induced biochemical, behavioral and histological alterations in a rat model of Huntington's disease.
    Shehata NI; Abd El-Salam DM; Hussein RM; Rizk SM
    PLoS One; 2023; 18(11):e0293660. PubMed ID: 37910529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Agmatine mitigates behavioral abnormalities and neurochemical dysregulation associated with 3-Nitropropionic acid-induced Huntington's disease in rats.
    Katariya R; Mishra K; Sammeta S; Umekar M; Kotagale N; Taksande B
    Neurotoxicology; 2024 May; 102():12-28. PubMed ID: 38453033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nicotinamide reverses behavioral impairments and provides neuroprotection in 3-nitropropionic acid induced animal model ofHuntington's disease: implication of oxidative stress- poly(ADP- ribose) polymerase pathway.
    Sidhu A; Diwan V; Kaur H; Bhateja D; Singh CK; Sharma S; Padi SSV
    Metab Brain Dis; 2018 Dec; 33(6):1911-1921. PubMed ID: 30054774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of LOX/COX pathways in 3-nitropropionic acid-induced Huntington's disease-like symptoms in rats: protective effect of licofelone.
    Kumar P; Kalonia H; Kumar A
    Br J Pharmacol; 2011 Sep; 164(2b):644-54. PubMed ID: 21486276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroprotective effect of solanesol against 3-nitropropionic acid-induced Huntington's disease-like behavioral, biochemical, and cellular alterations: Restoration of coenzyme-Q10-mediated mitochondrial dysfunction.
    Mehan S; Monga V; Rani M; Dudi R; Ghimire K
    Indian J Pharmacol; 2018; 50(6):309-319. PubMed ID: 30783323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inosine attenuates 3-nitropropionic acid-induced Huntington's disease-like symptoms in rats via the activation of the A2AR/BDNF/TrKB/ERK/CREB signaling pathway.
    El-Shamarka ME; El-Sahar AE; Saad MA; Assaf N; Sayed RH
    Life Sci; 2022 Jul; 300():120569. PubMed ID: 35472453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroprotective effect of taurine in 3-nitropropionic acid-induced experimental animal model of Huntington's disease phenotype.
    Tadros MG; Khalifa AE; Abdel-Naim AB; Arafa HM
    Pharmacol Biochem Behav; 2005 Nov; 82(3):574-82. PubMed ID: 16337998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Huntington's disease is a disorder of the corpus striatum: focus on Rhes (Ras homologue enriched in the striatum).
    Subramaniam S; Snyder SH
    Neuropharmacology; 2011 Jun; 60(7-8):1187-92. PubMed ID: 21044641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of an Angiotensin IV Analog on 3-Nitropropionic Acid-Induced Huntington's Disease-Like Symptoms in Rats.
    Wells RG; Azzam AF; Hiller AL; Sardinia MF
    J Huntingtons Dis; 2024; 13(1):55-66. PubMed ID: 38489193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protopanaxtriol protects against 3-nitropropionic acid-induced oxidative stress in a rat model of Huntington's disease.
    Gao Y; Chu SF; Li JP; Zhang Z; Yan JQ; Wen ZL; Xia CY; Mou Z; Wang ZZ; He WB; Guo XF; Wei GN; Chen NH
    Acta Pharmacol Sin; 2015 Mar; 36(3):311-22. PubMed ID: 25640478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.